DelveInsight's Mild Cognitive Impairment Market Insights report includes a comprehensive understanding of current treatment ...

CMD patients face a 2x higher risk of dementia and MCI, but healthier lifestyles can counter air pollution's impact and ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published.

According to DelveInsight's analysis, the mild cognitive impairment market is anticipated to increase during the forecast period (2024-2034), owing to the rise in the launch of emerging therapies ...

The intricate connection between gut health and brain function is increasingly capturing scientific interest. A ...

This is the 29 th published study on the use of BrainHQ in patients with MCI or other forms of pre-dementia. Prior studies ...

BioArctic announces US FDA accepts Eisai’s BLA for subcutaneous maintenance dosing of Leqembi: Stockholm Wednesday, January 15, 2025, 13:00 Hrs [IST] BioArctic AB (publ) announc ...

There are a range of substances that can contribute to the development of cognitive impairment, some of which may mimic a more serious cognitive disorder and others that might progress to a full ...

Repetitive transcranial magnetic stimulation (rTMS) added to tai chi chuan exercise improved sleep and cognition in older ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi ...